Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT00560794 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Blinatumomab (MT103)

Sponsor

Amgen Research (Munich) GmbH